Compare AQMS & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AQMS | NEUP |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | United States | United States |
| Employees | N/A | 8 |
| Industry | Metal Fabrications | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9M | 23.0M |
| IPO Year | 2015 | N/A |
| Metric | AQMS | NEUP |
|---|---|---|
| Price | $5.06 | $4.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $12.00 | ★ $21.00 |
| AVG Volume (30 Days) | ★ 82.2K | 25.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,100,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $550.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $3.65 |
| 52 Week High | $39.37 | $21.31 |
| Indicator | AQMS | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 43.75 | 57.93 |
| Support Level | $4.62 | $3.95 |
| Resistance Level | $8.37 | $4.43 |
| Average True Range (ATR) | 0.34 | 0.13 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 72.29 | 71.00 |
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.